The global point of care diagnostic market was valued at USD 28.5 billion in 2025. The market is projected to grow from USD 30.2 billion in 2026 to USD 56.74 billion by 2034, exhibiting a compound annual growth rate of 8.21% during the forecast period. Contrive Datum Insights presents this information in its report titled "Point Of Care Diagnostic Market Size, Share & Industry Analysis, By Technology (Lateral Flow Assays, Immunoassay-based Platforms, Biosensor-based Platforms, Molecular/PCR-based POC, Microfluidics-based Platforms), Product (Glucose Testing, Hb1Ac Testing, Coagulation Testing, Fertility/Pregnancy, Infectious Disease, HIV POC, Clostridium Difficile POC, HBV POC, Pneumonia or Streptococcus Associated Infections, HPV POC, Influenza/Flu POC, HCV POC, MRSA POC, TB and Drug-resistant TB POC, HSV POC, COVID-19, Other Infectious Diseases, Thyroid Stimulating Hormone, Hematology, Primary Care Systems, Feces, Lipid Testing, Cancer Marker, Blood Gas/Electrolytes, Ambulatory Chemistry, Drug of Abuse (DOA) Testing, Urinalysis/Nephrology), End-use (Hospitals, Home, Physician Office, Clinics, Laboratory, Pharmacy & Retail Clinics, Urgent Care Clinics, Non-practice Clinics, Assisted Living Healthcare Facilities), Sample type (Blood/Serum/Plasma, Urine, Nasal/Nasopharyngeal Swab, Saliva, Other), Distribution channel (Direct/Institutional Tender, Retail Pharmacy, Online/Direct-to-Consumer), and Regional Forecast, 2026-2034".
Point-of-care diagnostics are testing devices and assay systems designed to deliver a result at or near the site of patient care, rather than requiring a sample to be sent to a central laboratory. The category spans handheld meters, cartridge-based analyzers, lateral flow strips and benchtop instruments used to measure analytes such as glucose, infectious disease markers, cardiac and coagulation parameters, and hormones. Buyers include hospitals, physician offices, retail and urgent care clinics, public health programs and increasingly patients themselves testing at home.
Rising chronic disease burden driving decentralized glucose and cardiometabolic monitoring
Rising chronic disease burden driving decentralized glucose and cardiometabolic monitoring is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 8.21% a year, the technology lines exposed to it move fastest: Molecular/PCR-based POC compounds at 11.62%, taking its share of revenue from 15% to 20% and its value from USD 4.28 billion to USD 11.35 billion.
On the upside, the study's bull case assumes the bull case assumes faster clearance and reimbursement of molecular and biosensor point-of-care platforms alongside sustained expansion of home and retail testing access, which would take 2034 revenue to USD 64.12 billion against the USD 56.74 billion base case.
The downside is specific. The bear case assumes reimbursement tightening for point-of-care testing and a slower shift of infectious disease and chronic disease testing away from central laboratories than currently observed, and 2034 revenue lands at USD 49.65 billion. Lateral Flow Assays is the drag, 34% of the 2025 base compounding at 5.88% while the market runs at 8.21%.
Lateral Flow Assays Scale Against Molecular/PCR-based POC Momentum
The technology axis, not the regional one, is what divides the field. Lateral Flow Assays is the volume position, 34% of 2025 revenue at USD 9.69 billion, holding 28% through 2034, and it is defended by scale. Molecular/PCR-based POC is the growth position at 11.62%, and it is open. Strength in one does not carry into the other.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product | Glucose Testing | 18.81% · USD 5.36 billion | HPV POC 14.2% |
| End-use | Hospitals | 28% · USD 7.98 billion | Home 10.44% |
| Sample type | Blood/Serum/Plasma | 52% · USD 14.82 billion | Saliva 12.93% |
| Distribution channel | Direct/Institutional Tender | 62% · USD 17.67 billion | Online/Direct-to-Consumer 15.24% |
- Based on regional analysis, North America led the global point of care diagnostic market in 2025 with 38% of global revenue at USD 10.83 billion, reaching USD 19.29 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 26% in 2025 to 32% in 2034, with revenue growing from USD 7.41 billion to USD 18.17 billion.
- Middle East and Africa stays the smallest contributor across the period: 6% of revenue in 2025 and 6% in 2034.
- Lateral Flow Assays was the leading technology line in 2025, taking 34% of revenue at USD 9.69 billion.
- No technology line grows faster than Molecular/PCR-based POC, at a projected 11.62%.
- The United States is the largest single country market at USD 9.21 billion in 2025, 32.32% of global revenue.
The study covers five axes, by technology, and by product, end-use, sample type and distribution channel, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 49.65 billion and USD 64.12 billion by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.